Patent intelligence · US
US 10829485
ATF6 inhibitors and uses thereof
ATF6 inhibitors and uses thereof
Patent details — US 10829485
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 10, 2020
- Expiration
- Nov 5, 2040
- Applicant
- BLACK BELT TX LTD
- Claims
- 60
- CPC classes
- A61P, A61P35/00
Quick answer
US 10829485 (ATF6 inhibitors and uses thereof) is held by BLACK BELT TX LTD. Status: granted. Granted Nov 10, 2020. Expires Nov 5, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BLACK BELT TX LTD
- Grant date
- Expiration
- Claims
- 60
- CPC classes
- A61P, A61P35/00
More from BLACK BELT TX LTD
Related pharmaceutical patents in our USPTO index.
-
US 12343394
CD38 modulating antibody agents
granted -
US 12325699
Antibacterial compounds
granted -
US 12304964
CD38 modulating antibody
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12161717
CD38 modulating antibody agents
granted -
US 12162949
CD38 antibody
granted -
US 11897873
Kappa opioid receptor antagonists and products and methods related thereto
granted -
US 11780930
CD38 modulating antibody
granted
Frequently asked questions
What is US patent 10829485?
US 10829485 (ATF6 inhibitors and uses thereof) is held by BLACK BELT TX LTD. Status: granted. Granted Nov 10, 2020. Expires Nov 5, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10829485?
BLACK BELT TX LTD is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 10829485 expire?
Our index shows an expiration date of Nov 5, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.